

## Electronic Supplementary Information (ESI)

### A comparative study between Cu(INA)<sub>2</sub>-MOF and [Cu(INA)<sub>2</sub>(H<sub>2</sub>O)<sub>4</sub>] complex for a click reaction and the Biginelli reaction under solvent-free conditions

Julia C. Mansano Willig<sup>a</sup>, Gustavo Granetto<sup>a</sup>, Danielly Reginato<sup>a</sup>, Felipe R. Dutra<sup>a</sup>, Érica Fernanda Poruczinski<sup>a</sup>, Isadora M. de Oliveira<sup>b</sup>, Helio A. Stefani<sup>b</sup>, Silvia D. de Campos<sup>a</sup>, Élvio A. de Campos<sup>a</sup>, Flávia Manarin<sup>a</sup> and Giancarlo V. Botteselle<sup>a\*</sup>

<sup>a</sup>*Centro de Engenharias e Ciências Exatas-CECE, Universidade Estadual do Oeste do Paraná, Toledo, 85903-000, PR-Brazil.*

<sup>b</sup>*Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil.*

<sup>c</sup>*Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, 05508-000, SP-Brazil.*

\*e-mail: [giancarlo.botteselle@unioeste.br](mailto:giancarlo.botteselle@unioeste.br) or [gian.botteselle@gmail.com](mailto:gian.botteselle@gmail.com)


## Contents

**S1.** Characterization of Cu(INA)<sub>2</sub>-MOF and of [Cu(INA)<sub>2</sub>(H<sub>2</sub>O)<sub>4</sub>] complex


**S2.** NMR spectroscopic data

**S3.** <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for all compounds and HRMS of the compound **3i**


### S1. Characterization of Cu(INA)<sub>2</sub>-MOF and of [Cu(INA)<sub>2</sub>(H<sub>2</sub>O)<sub>4</sub>] complex




**Figure S1.** Infrared (IR) analysis of Cu-MOF before and after the reaction.




**Figure S2.** X-ray powder diffraction (XRD) analysis of Cu-MOF before and after the reaction.




**Figure S3.** Thermogravimetric analysis (TGA) of Cu-MOF before and after the reaction.



**Figure S4.** IR analysis of  $[\text{Cu}(\text{INA})_2(\text{H}_2\text{O})_4]$  complex after the reaction.




**Figure S5.** XRD analysis of  $[\text{Cu}(\text{INA})_2(\text{H}_2\text{O})_4]$  complex after the reaction.



**Figure S6.** TGA of  $[\text{Cu}(\text{INA})_2(\text{H}_2\text{O})_4]$  complex after the reaction.


## S2. NMR spectroscopic data

### 1-benzyl-4-phenyl-1*H*-1,2,3-triazole (3a)<sup>1</sup>




Purification by extraction with dichloromethane. m.p.: 129°C (Lit. 128-129 °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ = 7.78 (d, *J* = 7.8 Hz, 2H); 7.65 (s, 1H); 7.40-7.25 (m, 8H); 5.54 (s, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ = 148.2, 134.7, 130.6, 129.1, 128.8, 128.8, 128.2, 128.0, 125.7, 119.5, 54.2.

### 1-benzyl-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (3b)<sup>2</sup>




Purification by extraction with dichloromethane. m.p.: 144°C (Lit. 145 °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ = 7.64 (d, *J* = 8.4 Hz, 2H); 7.54 (s, 1H); 7.29-7.18 (m, 5H); 6.83 (d, *J* = 9.6 Hz, 2H); 5.46 (s, 2H); 3.72 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ = 159.8, 134.6, 129.1, 128.8, 128.1, 127.1, 122.9, 118.9, 114.3, 55.3, 54.3.

### 1-benzyl-4-(p-tolyl)-1*H*-1,2,3-triazole (3c)<sup>3</sup>




Purification by extraction with dichloromethane. m.p.: 154°C (Lit. 154-155 °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ = 7.6 (d, *J* = 8.1 Hz, 2H); 7.56 (s, 1H); 7.29-7.22 (m, 3H); 7.21-7.19 (m, 2H); 7.10 (d, *J* = 7.8 Hz, 2H); 5.45 (s, 2H); 2.26 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ = 138.1, 134.7, 129.5, 129.1, 128.8, 128.1, 127.6, 125.7, 119.4, 54.3, 21.7.

### 1-benzyl-4-(naphthalen-1-yl)-1*H*-1,2,3-triazole (3d)<sup>4</sup>




Purification by extraction with dichloromethane. m.p.: 190°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ = 7.85-7.80 (m, 2H); 7.61-7.53 (m, 4H); 7.37-7.27 (m, 7H); 5.52 (s, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ = 141.2, 140.5, 134.4, 129.2, 129.0, 128.8, 128.2, 127.5, 127.5, 127.4, 127.0, 126.2, 119.7, 54.5.

#### **4-(1-benzyl-1*H*-1,2,3-triazol-4-yl)aniline (3e)<sup>5</sup>**




Purification by extraction with dichloromethane. m.p.: 161 °C (Lit. 160-161 °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): δ = 7.61 (s, 1H); 7.54 (d, J = 8.6 Hz, 2H); 7.35-7.26 (m, 5H); 6.70 (d, J = 8.4 Hz, 2H); 5.54 (s, 2H), 3.75 (br, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 50 MHz): δ = 148.6, 146.5, 134.9, 129.1, 128.7, 128.0, 126.9, 121.1, 118.2, 115.2, 54.2.

#### **1-(4-methoxyphenyl)-4-phenyl-1*H*-1,2,3-triazole (3f)<sup>6</sup>**



Cu-MOF: Purification by extraction with dichloromethane. Cu-Complex: Purification by column chromatography, eluent: hexane/ethyl acetate 80:20. m.p.: 160 °C (Lit. 160-161 °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ = 8.05 (s, 2H); 7.82 (d, J = 7.8 Hz, 2H); 7.59 (d, J = 8.7 Hz, 2H); 7.39-7.25 (m, 3H); 6.94 (d, J = 8.7 Hz, 2H); 3.79 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): 159.9, 148.2, 130.6, 130.4, 128.9, 128.3, 125.8, 122.2, 117.8, 114.8, 55.6.


#### **4-(1-(4-methoxyphenyl)-1*H*-1,2,3-triazol-4-yl)aniline (3g)<sup>7</sup>**



Cu-MOF: Purification by extraction with dichloromethane. Cu-Complex: Purification by column chromatography, eluent: hexane/ethyl acetate 80:20. m.p.: 160 °C (Lit. 160-161 °C). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz): δ = 8.55 (s, 1H); 7.77 (d, J = 8.7 Hz, 2H); 7.63 (d, J = 8.4 Hz, 2H); 7.12 (d, J = 9 Hz, 2H); 6.78 (d, J = 8.1 Hz, 2H); 3.88 (s, 3H).


.  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz): 159.9, 146.8, 146.4, 130.9, 129.9, 127.2, 122.3, 115.4, 114.9, 113.9, 55.8.

**1-(4-methoxyphenyl)-4-(*p*-tolyl)-1*H*-1,2,3-triazole (3h)<sup>8</sup>**




Purification by extraction with dichloromethane. m.p.:  $^{\circ}\text{C}$  (Lit.  $^{\circ}\text{C}$ ).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  = 8.07 (s, 1H); 7.78 (d,  $J$  = 8 Hz, 2H); 7.65 (d,  $J$  = 8.8 Hz, 2H); 7.24 (d,  $J$  = 7.6 Hz, 2H); 7.00 (d,  $J$  = 8.8 Hz, 2H); 3.85 (s, 3H); 2.38 (s, 3H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz): 159.8, 138.2; 130.6, 129.6, 127.6, 125.7, 122.1, 117.6, 114.8, 55.6, 21.7.

**1-benzyl-4-(benzylselanyl)-1*H*-1,2,3-triazole (3i)**




Cu-MOF: Purification by extraction with dichloromethane. Cu-Complex: Purification by column chromatography, eluent: hexane/ethyl acetate 80:20. m.p.: 180  $^{\circ}\text{C}$ .  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz):  $\delta$  = 7.42-7.40 (m, 2H); 7.37-7.34 (m, 3H); 7.22-7.16 (m, 5H); 7.07 (s, 1H); 5.42 (s, 2H); 4.13 (s, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz): 146.6, 145.9, 134.7, 134.6, 133.5, 129.6, 129.1, 128.7, 127.9, 121.7, 54.1, 20.7. HRMS (APCI-ESI-TOF, positive mode) m/z calcd. for  $\text{C}_{16}\text{H}_{15}\text{N}_3\text{NaSe}$  [M+Na]: 352.0329; found 352.0205.

**1-benzyl-4-(phenylselanyl)-1*H*-1,2,3-triazole (3j)<sup>9</sup>**




Cu-MOF: Purification by extraction with dichloromethane. Cu-Complex: Purification by column chromatography, eluent: hexane/ethyl acetate 80:20. m.p.:  $^{\circ}\text{C}$  (Lit. 56-58  $^{\circ}\text{C}$ ).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz):  $\delta$  = 7.55 (s, 1H); 7.42-7.35 (m, 5H); 7.26-7.20 (m, 5H); 5.52 (s, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz): 134.2, 132.6, 131.4, 130.6, 129.3, 129.2, 128.9, 128.5, 128.1, 127.2, 54.3.

**1-benzyl-4-((phenylselanyl)methyl)-1*H*-1,2,3-triazole (3k)<sup>9</sup>**




Cu-MOF: Purification by extraction with dichloromethane. Cu-Complex: Purification by column chromatography, eluent: hexane/ethyl acetate 80:20. m.p.: 50°C (Lit. 35-36 °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ = 7.38-7.21 (m, 3H); 7.19-7.06 (m, 8H); 5.45 (s, 2H); 4.06 (s, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): 138.5, 134.4, 131.5, 129.1, 128.9, 128.8, 128.3, 128.1, 128.0, 126.9, 54.1, 32.0.

**Ethyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7a)<sup>10</sup>**




Purification by column chromatography, eluent: hexane/ethyl acetate 60:40. <sup>1</sup>H NMR (DMSO-d6, 300 MHz): δ = 7.96 (br, 1H); 7.25-7.19 (m, 5H); 5.67 (br, 1H); 5.33 (s, 1H); 4.01 (q, J = 7.2 Hz, 2H); 2.27 (s, 3H); 1.09 (t, J = 7.2 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ = 165.7, 153.3, 146.3, 143.8, 128.8, 128.1, 126.7, 101.5, 60.1, 55.9, 18.8, 14.2.

**Ethyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7b)<sup>10</sup>**




Purification by column chromatography, eluent: hexane/ethyl acetate 65:35. <sup>1</sup>H NMR (DMSO-d6, 300 MHz): δ = 9.11 (s, 1H); 7.63 (s, 1H); 7.14 (d, J = 8.4 Hz, 2H); 6.87 (d, J = 8.7 Hz, 2H); 5.10 (s, 1H); 3.98 (q, J = 7.2 Hz, 2H); 3.72 (s, 3H); 2.24 (s, 3H); 1.10 (t, J = 7.2 Hz, 3H); <sup>13</sup>C NMR (DMSO-d6, 75 MHz): δ = 165.3, 158.4, 152.1, 147.9, 137.0, 127.4, 113.7, 99.6, 59.1, 55.0, 53.3, 17.7, 14.1.

**Ethyl-4-(2-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7c)<sup>11</sup>**



Purification by column chromatography, eluent: hexane/ethyl acetate 65:35. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz): δ = 9.15 (s, 1H); 7.59 (s, 1H); 7.19-7.11 (m, 4H); 5.41 (s, 1H); 3.88 (q, *J* = 6.9 Hz, 2H); 2.41 (s, 3H); 2.29 (s, 3H); 0.98 (t, *J* = 7.2 Hz, 3H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 75 MHz): δ = 165.8, 152.6, 148.6, 142.4, 136.8, 129.3, 126.6, 99.9, 59.6, 54.1, 21.1, 18.2, 14.6.


**Ethyl-6-methyl-2-oxo-4-(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7d)<sup>11</sup>**



Purification by column chromatography, eluent: hexane/ethyl acetate 60:40. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz): δ = 9.15 (s, 1H); 7.68 (s, 1H); 6.54 (s, 2H); 5.13 (s, 1H); 4.03 (q, *J* = 7.2 Hz, 2H); 3.73 (s, 6H); 3.64 (s, 3H); 1.13 (t, *J* = 7.2, 3H); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 75 MHz): δ = 165.9, 153.2, 152.7, 148.9, 140.9, 104.0, 99.6, 60.4, 59.7, 56.3, 54.4, 18.2, 14.6.


**Ethyl-6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7e)**

<sup>11</sup>




Purification by column chromatography, eluent: hexane/ethyl acetate 60:40.  $^1\text{H}$  NMR (DMSO-d<sub>6</sub>, 300 MHz):  $\delta$  = 9.12 (s, 1H); 7.65 (s, 1H); 7.12 (s, 4H); 5.11 (s, 1H); 3.98 (q,  $J$  = 6.9 Hz, 2H); 2.26 (s, 3H); 2.24 (s, 3H); 1.10 (t,  $J$  = 6.9, 3H);  $^{13}\text{C}$  NMR (DMSO-d<sub>6</sub>, 75 MHz):  $\delta$  = 165.8, 152.6, 148.6, 142.4, 136.8, 129.3, 126.6, 99.9, 59.6, 54.1, 21.1, 18.2, 14.6.

**Ethyl-4-(3-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7f)<sup>12</sup>**




Purification by column chromatography, eluent: hexane/ethyl acetate 65:35.  $^1\text{H}$  NMR (DMSO-d<sub>6</sub>, 300 MHz):  $\delta$  = 9.32 (s, 1H); 9.13 (s, 1H); 7.66 (s, 1H); 7.09 (t,  $J$  = 7.8 Hz, 1H); 6.65 (m, 3H); 5.43 (s, 1H); 5.08 (s, 1H); 4.00 (q,  $J$  = 7.2 Hz, 2H); 2.24 (s, 3H); 1.12 (t,  $J$  = 7.2 Hz, 3H);  $^{13}\text{C}$  NMR (DMSO-d<sub>6</sub>, 75 MHz):  $\delta$  = 165.4, 157.3, 152.2, 148.0, 146.2, 129.2, 116.9, 114.1, 113.1, 99.4, 59.1, 53.8, 17.7, 14.0.

**Ethyl-6-methyl-4-(2-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7g)<sup>13</sup>**




Purification by column chromatography, eluent: hexane/ethyl acetate 65:35.  $^1\text{H}$  NMR (DMSO-d<sub>6</sub>, 300 MHz):  $\delta$  = 9.25 (s, 1H); 7.65 (s, 1H); 7.57 (d,  $J$  = 7.2 Hz, 1H); 7.37-7.29 (m, 2H); 7.18 (t,  $J$  = 7.2 Hz, 1H); 5.62 (s, 1H); 3.90 (q,  $J$  = 6.9 Hz, 2H); 2.31 (s, 3H); 0.99 (t,  $J$  = 6.9 Hz, 3H);  $^{13}\text{C}$  NMR (DMSO-d<sub>6</sub>, 75 MHz):  $\delta$  = 164.9, 151.2, 149.1, 143.3, 133.7, 132.5, 128.7, 128.3, 122.2, 98.2, 58.9, 54.0, 17.6, 13.9.

**Ethyl-6-methyl-2-oxo-4-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7h)<sup>14</sup>**




Purification by column chromatography, eluent: hexane/ethyl acetate 65:35.  $^1\text{H}$  NMR (DMSO-d<sub>6</sub>, 300 MHz):  $\delta$  = 9.09 (s, 1H); 8.51 (s, 1H) 7.76-7.58 (m, 2H); 7.25-7.23 (m, 2H); 5.21 (s, 1H); 3.97 (q,  $J$  = 6.9 Hz, 3H); 2.23 (s, 3H); 1.08 (t,  $J$  = 6.9 Hz, 3H);  $^{13}\text{C}$  NMR (DMSO-d<sub>6</sub>, 75 MHz):  $\delta$  = 165.3, 162.3, 152.3, 149.2, 148.9, 136.5, 122.5, 120.8, 98.04, 59.0, 55.7, 17.8, 14.0.

**Ethyl-6-methyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7i)<sup>10</sup>**




Purification by column chromatography, eluent: hexane/ethyl acetate 60:40.  $^1\text{H}$  NMR (DMSO-d<sub>6</sub>, 300 MHz):  $\delta$  = 9.21 (s, 1H); 8.31 (d,  $J$  = 8.1 Hz, 1H); 7.93 (d,  $J$  = 7.8 Hz, 1H); 7.84 (d,  $J$  = 9.0 Hz, 1H); 7.70 (s, 1H); 7.60-7.40 (m, 4H); 6.06 (s, 1H); 3.80 (q,  $J$  = 7.2 Hz, 2H); 2.36 (s, 3H); 0.81 (q,  $J$  = 7.2 Hz, 3H);  $^{13}\text{C}$  NMR (DMSO-d<sub>6</sub>, 75 MHz):  $\delta$  = 165.2, 151.6, 148.6, 140.4, 133.4, 130.0, 128.4, 127.8, 125.9, 125.6, 125.5, 124.1, 123.6, 99.1, 58.9, 49.8, 17.7, 13.7.


**S3.  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for all compounds and HRMS for compound 3i**




**Figure S7.** NMR  $^1\text{H}$  spectrum (300 MHz,  $\text{CDCl}_3$ ) of product 3a.




**Figure S8.** NMR  $^{13}\text{C}$  spectrum (75 MHz,  $\text{CDCl}_3$ ) of product 3a.




**Figure S9.** NMR <sup>1</sup>H spectrum (300 MHz, CDCl<sub>3</sub>) of product 3b.




**Figure S10.** NMR <sup>13</sup>C spectrum (75 MHz, CDCl<sub>3</sub>) of product 3b.




**Figure S11.** NMR  $^1\text{H}$  spectrum (300 MHz,  $\text{CDCl}_3$ ) of product **3c**.




**FigureS12.** NMR  $^{13}\text{C}$  spectrum (75 MHz,  $\text{CDCl}_3$ ) of product **3c**.




**Figure S13.** NMR <sup>1</sup>H spectrum (300 MHz, CDCl<sub>3</sub>) of product 3d.




**Figure S14.** NMR <sup>13</sup>C spectrum (75 MHz, CDCl<sub>3</sub>) of product 3d.




**Figure S15.** NMR <sup>1</sup>H spectrum (200 MHz, CDCl<sub>3</sub>) of product **3e**.




**Figure S16.** NMR <sup>13</sup>C spectrum (50 MHz, CDCl<sub>3</sub>) of product **3e**.




**Figure S17.** NMR <sup>1</sup>H spectrum (300 MHz, CDCl<sub>3</sub>) of product 3f.




**Figure S18.** NMR <sup>13</sup>C spectrum (75 MHz, CDCl<sub>3</sub>) of product 3f.




**Figure S19.** NMR  $^1\text{H}$  spectrum (300 MHz,  $\text{CD}_3\text{OD}$ ) of product **3g**.




**Figure S20.** NMR  $^{13}\text{C}$  spectrum (75 MHz,  $\text{CDCl}_3$ ) of product **3g**.




**Figure S21.** NMR <sup>1</sup>H spectrum (300 MHz, CDCl<sub>3</sub>) of product 3h.




**Figure S22.** NMR <sup>13</sup>C spectrum (75 MHz, CDCl<sub>3</sub>) of product 3h.




**Figure S23.** NMR <sup>1</sup>H spectrum (300 MHz, CDCl<sub>3</sub>) of product 3i.




**Figure S24.** NMR <sup>13</sup>C spectrum (75 MHz, CDCl<sub>3</sub>) of product 3i.




**Figure S25.** NMR  $^1\text{H}$  spectrum (300 MHz,  $\text{CDCl}_3$ ) of product **3j**.




**Figure S26.** NMR  $^{13}\text{C}$  spectrum (75 MHz,  $\text{CDCl}_3$ ) of product **3j**.




**Figure S27.** NMR <sup>1</sup>H spectrum (300 MHz, CDCl<sub>3</sub>) of product 3k.




**Figure S28.** NMR <sup>13</sup>C spectrum (75 MHz, CDCl<sub>3</sub>) of product 3k.




**Figure S29.** NMR  $^1\text{H}$  spectrum (300 MHz, DMSO deuterated) of product **7a**.




**Figure S30.** NMR  $^{13}\text{C}$  spectrum (75 MHz, CDCl<sub>3</sub>) of product **7a**.




**Figure S31.** NMR  $^1\text{H}$  spectrum (300 MHz, DMSO-d<sub>6</sub>) of product **7b**.




**Figure S32.** NMR  $^{13}\text{C}$  spectrum (75 MHz, DMSO-d<sub>6</sub>) of product **7b**.




**Figure S33.** NMR <sup>1</sup>H spectrum (300 MHz, DMSO-d<sub>6</sub>) of product 7c.




**Figure S34.** NMR <sup>13</sup>C spectrum (75 MHz, DMSO-d<sub>6</sub>) of product 7c.




**Figure S35.** NMR  $^1\text{H}$  spectrum (300 MHz, DMSO-d<sub>6</sub>) of product **7d**.




**Figure S36.** NMR  $^{13}\text{C}$  spectrum (75 MHz, DMSO-d<sub>6</sub>) of product **7d**.




**Figure S37.** NMR <sup>1</sup>H spectrum (300 MHz, DMSO-d<sub>6</sub>) of product **7e**.




**Figure S38.** NMR <sup>13</sup>C spectrum (75 MHz, DMSO-d<sub>6</sub>) of product **7e**.




**Figure S39.** NMR <sup>1</sup>H spectrum (300 MHz, DMSO-d<sub>6</sub>) of product 7f.




**Figure S40.** NMR <sup>13</sup>C spectrum (75 MHz, DMSO-d<sub>6</sub>) of product 7f.




**Figure S41.** NMR  $^1\text{H}$  spectrum (300 MHz, DMSO-d<sub>6</sub>) of product **7g**.




**Figure S42.** NMR  $^{13}\text{C}$  spectrum (75 MHz, DMSO-d<sub>6</sub>) of product **7g**.




**Figure S43.** NMR  $^1\text{H}$  spectrum (300 MHz, DMSO-d6) of product **7h**.




**Figure S44.** NMR  $^{13}\text{C}$  spectrum (75 MHz, DMSO-d6) of product **7h**.




**Figure S45.** NMR  $^1\text{H}$  spectrum (300 MHz, DMSO-d6) of product **7i**.



**Figure S46.** NMR  $^{13}\text{C}$  spectrum (75 MHz, DMSO-d6) of product **7i**.



**Figure S47.** NMR <sup>1</sup>H spectrum (400 MHz,  $\text{CDCl}_3$ ) of a mixture of 1,4- and 1,5-disubstituted (1:1.4) triazole (**3j**).



**Figure S48.** HRMS spectra of compound **3i**.

## REFERENCES

- 1 J. Doiron, A. H. Soultan, R. Richard, M. M. Touré, N. Picot, R. Richard, M. Čuperlović-Culf, G. A. Robichaud and M. Touaibia, *Eur. J. Med. Chem.*, 2011, **46**, 4010–4024.
- 2 L. S. Campbell-Verduyn, L. Mirfeizi, R. A. Dierckx, P. H. Elsinga and B. L. Feringa, *Chem. Commun.*, 2009, 2139–2141.
- 3 J. R. Suárez, B. Trastoy, M. E. Pérez-Ojeda, R. Marín-Barrios and J. L. Chiara, *Adv. Synth. Catal.*, 2010, **352**, 2515–2520.
- 4 P. Sharma, J. Rathod, A. P. Singh, P. Kumar and Y. Sasson, *Catal. Sci. Technol.*, 2018, **8**, 3246–3259.
- 5 J. I. Sarmiento-Sánchez, A. Ochoa-Terán and I. A. Rivero, *Arkivoc*, 2011, **2011**, 177–188.
- 6 X. Meng, X. Xu, T. Gao and B. Chen, *European J. Org. Chem.*, 2010, 5409–5414.
- 7 F. Pagliai, T. Pirali, E. Del Grosso, R. Di Brisco, G. C. Tron, G. Sorba and A. A. Genazzani, *J. Med. Chem.*, 2006, **49**, 467–470.
- 8 J. Yan and L. Wang, *Synthesis (Stuttg.)*, 2010, 447–452.
- 9 M. T. Saraiva, N. Seus, D. De Souza, O. E. D. Rodrigues, M. W. Paixão, R. G. Jacob, E. J. Lenardão, G. Perin and D. Alves, *Synth.*, 2012, **44**, 1997–2004.
- 10 J. S. Yadav, B. V. Subba Reddy, P. Sridhar, J. S. S. Reddy, K. Nagaiah, N. Lingaiah and P. S. Saiprasad, *European J. Org. Chem.*, 2004, 552–557.
- 11 A. R. Hajipour, L. Khazdooz and A. Zarei, *Synth. Commun.*, 2011, **41**, 2200–2208.
- 12 K. K. Pasunooti, H. Chai, C. N. Jensen, B. K. Gorityala, S. Wang and X. W. Liu, *Tetrahedron Lett.*, 2011, **52**, 80–84.
- 13 S. P. Maradur and G. S. Gokavi, *Catal. Commun.*, 2007, **8**, 279–284.
- 14 W. Li, G. Zhou, P. Zhang, Y. Lai and S. Xu, *Heterocycles*, 2011, **83**, 2067–2077.